These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 22186738)

  • 1. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration.
    Rauch R; Weingessel B; Maca SM; Vecsei-Marlovits PV
    Retina; 2012 Jul; 32(7):1260-4. PubMed ID: 22186738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
    Saito M; Iida T; Kano M
    Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration.
    Lala C; Framme C; Wolf-Schnurrbusch UE; Wolf S
    Acta Ophthalmol; 2013 Sep; 91(6):526-30. PubMed ID: 22697404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.
    Cho HJ; Kim CG; Yoo SJ; Cho SW; Lee DW; Kim JW; Lee JH
    Am J Ophthalmol; 2013 Jan; 155(1):118-126.e1. PubMed ID: 23022163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).
    Nguyen QD; Schachar RA; Nduaka CI; Sperling M; Klamerus KJ; Chi-Burris K; Yan E; Paggiarino DA; Rosenblatt I; Aitchison R; Erlich SS;
    Ophthalmology; 2012 Sep; 119(9):1867-73. PubMed ID: 22683252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity.
    Axer-Siegel R; Bor E; Bourla DH; Weinberger D; Mimouni K
    Retina; 2012 Oct; 32(9):1811-20. PubMed ID: 22825407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
    Park SS; Daftari I; Phillips T; Morse LS
    Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings.
    Cohen SY; Oubraham H; Uzzan J; Dubois L; Tadayoni R
    Retina; 2012 Sep; 32(8):1480-5. PubMed ID: 22258164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks.
    Lushchyk T; Amarakoon S; Martinez-Ciriano JP; van den Born LI; Baarsma GS; Missotten T
    Acta Ophthalmol; 2013 Sep; 91(6):e456-61. PubMed ID: 23773796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab for neovascular age-related macular degeneration in China.
    Li X; Hu Y; Sun X; Zhang J; Zhang M;
    Ophthalmology; 2012 Oct; 119(10):2087-93. PubMed ID: 22818896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
    Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
    Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity.
    El-Mollayess GM; Mahfoud Z; Schakal AR; Salti HI; Jaafar D; Bashshur ZF
    Retina; 2013 Oct; 33(9):1828-35. PubMed ID: 23615342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
    Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
    Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of fixation in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
    Mathew R; Pearce E; Sivaprasad S
    Am J Ophthalmol; 2012 Mar; 153(3):490-496.e1. PubMed ID: 22071230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration.
    Gomi F; Sawa M; Tsujikawa M; Nishida K
    Retina; 2012 Oct; 32(9):1804-10. PubMed ID: 22718152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
    Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
    Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.